Wells Fargo & Company Viracta Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 171 shares of VIRX stock, worth $27. This represents 0.0% of its overall portfolio holdings.

Number of Shares

171

Previous 171 -0.0%

Holding current value

$27

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.5 - $1.17 $107 - $250	-214 Reduced 55.58%	171 $0
Q1 2024 May 10, 2024	BUY	$0.48 - $1.13 $1 - $3	3 Added 0.79%	385 $0
Q4 2023 Feb 09, 2024	BUY	$0.44 - $1.04 $5 - $12	12 Added 3.24%	382 $0
Q3 2023 Nov 13, 2023	BUY	$1.03 - $1.58 $27 - $42	27 Added 7.87%	370 $0
Q2 2023 Aug 15, 2023	BUY	$0.89 - $2.13 $7 - $17	8 Added 2.39%	343 $0
Q1 2023 May 12, 2023	BUY	$1.38 - $2.29 $4 - $6	3 Added 0.9%	335 $0
Q4 2022 Feb 13, 2023	BUY	$1.26 - $4.38 $7 - $26	6 Added 1.84%	332 $0
Q3 2022 Nov 14, 2022	BUY	$3.32 - $5.69 $76 - $130	23 Added 7.59%	326 $2,000
Q2 2022 Aug 12, 2022	SELL	$1.87 - $5.0 $121,046 - $323,655	-64,731 Reduced 99.53%	303 $1,000
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $24,139 - $51,527	-10,825 Reduced 14.27%	65,034 $310,000
Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $220,590 - $517,764	65,457 Added 629.27%	75,859 $277,000
Q3 2021 Nov 15, 2021	BUY	$7.84 - $12.53 $68,113 - $108,860	8,688 Added 506.88%	10,402 $83,000
Q2 2021 Aug 16, 2021	SELL	$7.55 - $12.95 $47,051 - $80,704	-6,232 Reduced 78.43%	1,714 $19,000
Q1 2021 May 13, 2021	BUY	$7.58 - $18.67 $60,230 - $148,351	7,946 New	7,946 $73,000

Others Institutions Holding VIRX

# of Institutions

Shares Held

5.63M

Call Options Held

Put Options Held

View Full List

About Viracta Therapeutics, Inc.

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $6.01M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

More about VIRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Viracta Therapeutics, Inc. Transaction History